Why some tumor-fighting T cells get stuck in nearby lymph nodes after cancer vaccines

Lymphoid residency of Tcf-1+ CD8+ T cells during tumor vaccine responses

NIH-funded research University of Texas Hlth Science Center · NIH-11241981

This research looks at why a special group of tumor-fighting T cells remain trapped in tumor-draining lymph nodes after cancer vaccine responses, with the goal of helping people with advanced cancers get stronger, longer-lasting immune help.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Texas Hlth Science Center NIH-funded
Lab location1 site (San Antonio, United States)
Project IDNIH-11241981 on NIH RePORTER

What this research studies

You’ll hear about a type of “stem-like” CD8 T cell that helps keep anti-cancer immunity going, and the team will study how these cells behave after tumor vaccines. They will track whether these cells become resident inside tumor-draining lymph nodes instead of traveling to tumors, using laboratory analyses and comparisons of cells from lymph nodes and tumors. The researchers will map the development and lineage relationships of these cells to understand why they lose their migratory ability. Findings could point to ways to change vaccine or combination treatments so more immune cells reach and attack tumors.

Who could benefit from this research

Good fit: People with advanced cancers—especially those receiving or eligible for tumor vaccines or other immunotherapies—would be the most relevant candidates for related clinical work.

Not a fit: People without cancer or those whose treatment plans do not involve vaccines or immune-based therapies are unlikely to see direct benefit from this specific research.

Why it matters

Potential benefit: If successful, this work could help design vaccines or combination therapies that free and boost tumor-fighting T cells, improving durable responses to cancer immunotherapies.

How similar studies have performed: Prior studies have shown that 'stem-like' T cells are important for durable immunotherapy responses, but the idea that many become lymph-node resident after vaccine responses is a newer finding that has not yet been translated into proven patient treatments.

Where this research is happening

San Antonio, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Advanced Cancer
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.